Prognostic value of Aurora B expression in cancer patients: A meta-analysis.

IF 2 4区医学 Q3 ONCOLOGY

Tumori Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI:10.1177/03008916251343384

Md Mojahidur Hasan, Sehreen Tory, Yusuf Kemal Arslan, Yasemin Saygideger, Yusuf Tutar

{"title":"Prognostic value of Aurora B expression in cancer patients: A meta-analysis.","authors":"Md Mojahidur Hasan, Sehreen Tory, Yusuf Kemal Arslan, Yasemin Saygideger, Yusuf Tutar","doi":"10.1177/03008916251343384","DOIUrl":null,"url":null,"abstract":"Background: Overexpression of Aurora B is linked to poor prognosis in various malignancies; however, its prognostic role remains debatable. Conducting a meta-analysis is essential to reach a definitive conclusion.Methods: Various databases were searched. Aurora B protein expression was assessed for prognostic significance using pooled hazard ratio (HR) with a 95% confidence interval (CI). Meta-regression and subgroup analysis identified the source of heterogeneity.Results: The study comprised 1384 cancer patients from 10 articles. The result with multivariate data (pooled HR=1.18, 95% CI= 0.71-1.95, p=0.52, I²=83%) and univariate data (pooled HR=1.81, 95% CI=0.92, 3.57, p=0.09, I2=89%) showed that increased Aurora B expression was not linked with poor overall survival (OS). Subgroup analysis showed that sample size, follow-up time, cut-off value, non-Chinese patients, antibody source were not associated with unfavorable OS.Conclusions: Aurora B expression could not be used as a prognostic marker in cancer.","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"253-260"},"PeriodicalIF":2.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916251343384","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Overexpression of Aurora B is linked to poor prognosis in various malignancies; however, its prognostic role remains debatable. Conducting a meta-analysis is essential to reach a definitive conclusion.

Methods: Various databases were searched. Aurora B protein expression was assessed for prognostic significance using pooled hazard ratio (HR) with a 95% confidence interval (CI). Meta-regression and subgroup analysis identified the source of heterogeneity.

Results: The study comprised 1384 cancer patients from 10 articles. The result with multivariate data (pooled HR=1.18, 95% CI= 0.71-1.95, p=0.52, I²=83%) and univariate data (pooled HR=1.81, 95% CI=0.92, 3.57, p=0.09, I²=89%) showed that increased Aurora B expression was not linked with poor overall survival (OS). Subgroup analysis showed that sample size, follow-up time, cut-off value, non-Chinese patients, antibody source were not associated with unfavorable OS.

Conclusions: Aurora B expression could not be used as a prognostic marker in cancer.

查看原文本刊更多论文

Aurora B表达在癌症患者中的预后价值：一项荟萃分析。

背景：在多种恶性肿瘤中，极光B的过表达与预后不良有关；然而，其预测作用仍有争议。进行荟萃分析对于得出明确的结论至关重要。方法检索各种数据库。采用合并风险比（HR）和95%可信区间（CI）评估Aurora B蛋白表达的预后意义。meta回归和亚组分析确定了异质性的来源。结果：该研究包括来自10篇文章的1384名癌症患者。多变量数据（合并HR=1.18, 95% CI= 0.71-1.95, p=0.52, I²=83%）和单变量数据（合并HR=1.81, 95% CI=0.92, 3.57, p=0.09, I2=89%）的结果显示，Aurora B表达增加与总生存期（OS）较差无关。亚组分析显示，样本量、随访时间、临界值、非中国籍患者、抗体来源与不良OS无相关性。结论：Aurora B的表达不能作为癌症的预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.